Sulfiredoxin Promotes Cancer Cell Invasion through Regulation of the miR143-Fascin Axis

REFERENCES

• Siegel RL, Miller KD, Jemal A. 2020. Cancer statistics, 2020. CA Cancer J Clin 70:7–30. https://doi.org/10.3322/caac.21590.
   PubMed Web of Science ®Google Scholar
• Biteau B, Labarre J, Toledano MB. 2003. ATP-dependent reduction of cysteine-sulphinic acid by S. cerevisiae sulphiredoxin. Nature 425:980–984. https://doi.org/10.1038/nature02075.
   PubMed Web of Science ®Google Scholar
• Chang TS, Jeong W, Woo HA, Lee SM, Park S, Rhee SG. 2004. Characterization of mammalian sulfiredoxin and its reactivation of hyperoxidized peroxiredoxin through reduction of cysteine sulfinic acid in the active site to cysteine. J Biol Chem 279:50994–51001. https://doi.org/10.1074/jbc.M409482200.
   PubMed Web of Science ®Google Scholar
• Matthews CP, Birkholz AM, Baker AR, Perella CM, Beck GR, Jr, Young MR, Colburn NH. 2007. Dominant-negative activator protein 1 (TAM67) targets cyclooxygenase-2 and osteopontin under conditions in which it specifically inhibits tumorigenesis. Cancer Res 67:2430–2438. https://doi.org/10.1158/0008-5472.CAN-06-0522.
   PubMed Web of Science ®Google Scholar
• Wei Q, Jiang H, Matthews CP, Colburn NH. 2008. Sulfiredoxin is an AP-1 target gene that is required for transformation and shows elevated expression in human skin malignancies. Proc Natl Acad Sci USA 105:19738–19743. https://doi.org/10.1073/pnas.0810676105.
   PubMed Web of Science ®Google Scholar
• Wei Q, Jiang H, Xiao Z, Baker A, Young MR, Veenstra TD, Colburn NH. 2011. Sulfiredoxin-peroxiredoxin IV axis promotes human lung cancer progression through modulation of specific phosphokinase signaling. Proc Natl Acad Sci USA 108:7004–7009. https://doi.org/10.1073/pnas.1013012108.
   PubMed Web of Science ®Google Scholar
• Merikallio H, Paakko P, Kinnula VL, Harju T, Soini Y. 2011. Nuclear factor erythroid-derived 2-like 2 (Nrf2) and DJ1 are prognostic factors in lung cancer. Hum Pathol 43:577–584. https://doi.org/10.1016/j.humpath.2011.05.024.
   PubMed Web of Science ®Google Scholar
• Wei Q, Jiang H, Baker A, Dodge LK, Gerard M, Young MR, Toledano MB, Colburn NH. 2013. Loss of sulfiredoxin renders mice resistant to azoxymethane/dextran sulfate sodium-induced colon carcinogenesis. Carcinogenesis 34:1403–1410. https://doi.org/10.1093/carcin/bgt059.
   PubMed Web of Science ®Google Scholar
• Jonsson TJ, Johnson LC, Lowther WT. 2008. Structure of the sulphiredoxin-peroxiredoxin complex reveals an essential repair embrace. Nature 451:98–101. https://doi.org/10.1038/nature06415.
   PubMed Web of Science ®Google Scholar
• Murphy DA, Courtneidge SA. 2011. The ‘ins’ and ‘outs’ of podosomes and invadopodia: characteristics, formation and function. Nat Rev Mol Cell Biol 12:413–426. https://doi.org/10.1038/nrm3141.
   PubMed Web of Science ®Google Scholar
• Paz H, Pathak N, Yang J. 2014. Invading one step at a time: the role of invadopodia in tumor metastasis. Oncogene 33:4193–4202. https://doi.org/10.1038/onc.2013.393.
   PubMed Web of Science ®Google Scholar
• Revach OY, Grosheva I, Geiger B. 2020. Biomechanical regulation of focal adhesion and invadopodia formation. J Cell Sci 133:jcs244848. https://doi.org/10.1242/jcs.244848.
   PubMed Web of Science ®Google Scholar
• Lamb MC, Tootle TL. 2020. Fascin in cell migration: more than an actin bundling protein. Biology (Basel) 9:403. https://doi.org/10.3390/biology9110403.
   PubMedGoogle Scholar
• Lin S, Taylor MD, Singh PK, Yang S. 2020. How does fascin promote cancer metastasis? FEBS J 88:1434–1446. https://doi.org/10.1111/febs.15484.
   Google Scholar
• Jonas S, Izaurralde E. 2015. Towards a molecular understanding of microRNA-mediated gene silencing. Nat Rev Genet 16:421–433. https://doi.org/10.1038/nrg3965.
   PubMed Web of Science ®Google Scholar
• Perez-Ortin JE, Alepuz P, Chavez S, Choder M. 2013. Eukaryotic mRNA decay: methodologies, pathways, and links to other stages of gene expression. J Mol Biol 425:3750–3775. https://doi.org/10.1016/j.jmb.2013.02.029.
   PubMed Web of Science ®Google Scholar
• Harris IS, DeNicola GM. 2020. The Complex Interplay between Antioxidants and ROS in Cancer. Trends Cell Biol 30:440–451. https://doi.org/10.1016/j.tcb.2020.03.002.
   PubMed Web of Science ®Google Scholar
• George S, Abrahamse H. 2020. Redox potential of antioxidants in cancer progression and prevention. Antioxidants (Basel) 9:1156. https://doi.org/10.3390/antiox9111156.
   PubMedGoogle Scholar
• Sun Y, Hegamyer G, Colburn NH. 1994. Molecular cloning of five messenger RNAs differentially expressed in preneoplastic or neoplastic JB6 mouse epidermal cells: one is homologous to human tissue inhibitor of metalloproteinases-3. Cancer Res 54:1139–1144.
   PubMed Web of Science ®Google Scholar
• Roussel X, Boukhenouna S, Rahuel-Clermont S, Branlant G. 2011. The rate-limiting step of sulfiredoxin is associated with the transfer of the gamma-phosphate of ATP to the sulfinic acid of overoxidized typical 2-Cys peroxiredoxins. FEBS Lett 585:574–578. https://doi.org/10.1016/j.febslet.2011.01.012.
   PubMed Web of Science ®Google Scholar
• Roussel X, Bechade G, Kriznik A, Van Dorsselaer A, Sanglier-Cianferani S, Branlant G, Rahuel-Clermont S. 2008. Evidence for the formation of a covalent thiosulfinate intermediate with peroxiredoxin in the catalytic mechanism of sulfiredoxin. J Biol Chem 283:22371–22382. https://doi.org/10.1074/jbc.M800493200.
   PubMed Web of Science ®Google Scholar
• Jonsson TJ, Johnson LC, Lowther WT. 2009. Protein engineering of the quaternary sulfiredoxin·peroxiredoxin enzyme·substrate complex reveals the molecular basis for cysteine sulfinic acid phosphorylation. J Biol Chem 284:33305–33310. https://doi.org/10.1074/jbc.M109.036400.
   PubMed Web of Science ®Google Scholar
• Findlay VJ, Townsend DM, Morris TE, Fraser JP, He L, Tew KD. 2006. A novel role for human sulfiredoxin in the reversal of glutathionylation. Cancer Res 66:6800–6806. https://doi.org/10.1158/0008-5472.CAN-06-0484.
   PubMed Web of Science ®Google Scholar
• Park JW, Mieyal JJ, Rhee SG, Chock PB. 2009. Deglutathionylation of 2-Cys peroxiredoxin is specifically catalyzed by sulfiredoxin. J Biol Chem 284:23364–23374. https://doi.org/10.1074/jbc.M109.021394.
   PubMed Web of Science ®Google Scholar
• Findlay VJ, Tapiero H, Townsend DM. 2005. Sulfiredoxin: a potential therapeutic agent? Biomed Pharmacother 59:374–379. https://doi.org/10.1016/j.biopha.2005.07.003.
   PubMed Web of Science ®Google Scholar
• Planson AG, Palais G, Abbas K, Gerard M, Couvelard L, Delaunay A, Baulande S, Drapier JC, Toledano MB. 2011. Sulfiredoxin protects mice from lipopolysaccharide-induced endotoxic shock. Antioxid Redox Signal 14:2071–2080. https://doi.org/10.1089/ars.2010.3552.
   PubMed Web of Science ®Google Scholar
• Wu L, Jiang H, Chawsheen HA, Mishra M, Young MR, Gerard M, Toledano MB, Colburn NH, Wei Q. 2014. Tumor promoter-induced sulfiredoxin is required for mouse skin tumorigenesis. Carcinogenesis 35:1177–1184. https://doi.org/10.1093/carcin/bgu035.
   PubMed Web of Science ®Google Scholar
• Kim YS, Lee HL, Lee KB, Park JH, Chung WY, Lee KS, Sheen SS, Park KJ, Hwang SC. 2011. Nuclear factor E2-related factor 2 dependent overexpression of sulfiredoxin and peroxiredoxin III in human lung cancer. Korean J Intern Med 26:304–313. https://doi.org/10.3904/kjim.2011.26.3.304.
   PubMedGoogle Scholar
• Bowers RR, Manevich Y, Townsend DM, Tew KD. 2012. Sulfiredoxin redox-sensitive interaction with S100A4 and non-muscle myosin IIA regulates cancer cell motility. Biochemistry 51:7740–7754. https://doi.org/10.1021/bi301006w.
   PubMed Web of Science ®Google Scholar
• Hartikainen JM, Tengstrom M, Kosma VM, Kinnula VL, Mannermaa A, Soini Y. 2012. Genetic polymorphisms and protein expression of NRF2 and sulfiredoxin predict survival outcomes in breast cancer. Cancer Res 72:5537–5546. https://doi.org/10.1158/0008-5472.CAN-12-1474.
   PubMed Web of Science ®Google Scholar
• Jeong W, Bae SH, Toledano MB, Rhee SG. 2012. Role of sulfiredoxin as a regulator of peroxiredoxin function and regulation of its expression. Free Radic Biol Med 53:447–456. https://doi.org/10.1016/j.freeradbiomed.2012.05.020.
   PubMed Web of Science ®Google Scholar
• Molin M, Yang J, Hanzen S, Toledano MB, Labarre J, Nystrom T. 2011. Life span extension and H2O2 resistance elicited by caloric restriction require the peroxiredoxin Tsa1 in Saccharomyces cerevisiae. Mol Cell 43:823–833. https://doi.org/10.1016/j.molcel.2011.07.027.
   PubMed Web of Science ®Google Scholar
• Jiang H, Wu L, Chen J, Mishra M, Chawsheen HA, Zhu H, Wei Q. 2015. Sulfiredoxin promotes colorectal cancer cell invasion and metastasis through a novel mechanism of enhancing EGFR signaling. Mol Cancer Res 13:1554–1566. https://doi.org/10.1158/1541-7786.MCR-15-0240.
   PubMed Web of Science ®Google Scholar
• Moon JC, Kim GM, Kim EK, Lee HN, Ha B, Lee SY, Jang HH. 2013. Reversal of 2-Cys peroxiredoxin oligomerization by sulfiredoxin. Biochem Biophys Res Commun 432:291–295. https://doi.org/10.1016/j.bbrc.2013.01.114.
   PubMed Web of Science ®Google Scholar
• Konig J, Galliardt H, Jutte P, Schaper S, Dittmann L, Dietz KJ. 2013. The conformational bases for the two functionalities of 2-cysteine peroxiredoxins as peroxidase and chaperone. J Exp Bot 64:3483–3497. https://doi.org/10.1093/jxb/ert184.
   PubMed Web of Science ®Google Scholar
• Jang HH, Lee KO, Chi YH, Jung BG, Park SK, Park JH, Lee JR, Lee SS, Moon JC, Yun JW, Choi YO, Kim WY, Kang JS, Cheong GW, Yun DJ, Rhee SG, Cho MJ, Lee SY. 2004. Two enzymes in one; two yeast peroxiredoxins display oxidative stress-dependent switching from a peroxidase to a molecular chaperone function. Cell 117:625–635. https://doi.org/10.1016/j.cell.2004.05.002.
   PubMed Web of Science ®Google Scholar
• Kureishy N, Sapountzi V, Prag S, Anilkumar N, Adams JC. 2002. Fascins, and their roles in cell structure and function. Bioessays 24:350–361. https://doi.org/10.1002/bies.10070.
   PubMed Web of Science ®Google Scholar
• Jayo A, Parsons M. 2010. Fascin: a key regulator of cytoskeletal dynamics. Int J Biochem Cell Biol 42:1614–1617. https://doi.org/10.1016/j.biocel.2010.06.019.
   PubMed Web of Science ®Google Scholar
• Chen L, Yang S, Jakoncic J, Zhang JJ, Huang XY. 2010. Migrastatin analogues target fascin to block tumour metastasis. Nature 464:1062–1066. https://doi.org/10.1038/nature08978.
   PubMed Web of Science ®Google Scholar
• Adams JC. 2004. Roles of fascin in cell adhesion and motility. Curr Opin Cell Biol 16:590–596. https://doi.org/10.1016/j.ceb.2004.07.009.
   PubMed Web of Science ®Google Scholar
• Zhang FR, Tao LH, Shen ZY, Lv Z, Xu LY, Li EM. 2008. Fascin expression in human embryonic, fetal, and normal adult tissue. J Histochem Cytochem 56:193–199. https://doi.org/10.1369/jhc.7A7353.2007.
   PubMed Web of Science ®Google Scholar
• Li L, Cao F, Liu B, Luo X, Ma X, Hu Z. 2015. TGF-β induces fascin expression in gastric cancer via phosphorylation of smad3 linker area. Am J Cancer Res 5:1890–1896.
   PubMed Web of Science ®Google Scholar
• Snyder M, Huang J, Huang XY, Zhang JJ. 2014. A signal transducer and activator of transcription 3·nuclear factor κB (Stat3.NFκB) complex is necessary for the expression of fascin in metastatic breast cancer cells in response to interleukin (IL)-6 and tumor necrosis factor (TNF)-α. J Biol Chem 289:30082–30089. https://doi.org/10.1074/jbc.M114.591719.
   PubMed Web of Science ®Google Scholar
• Zhao X, Gao S, Ren H, Sun W, Zhang H, Sun J, Yang S, Hao J. 2014. Hypoxia-inducible factor-1 promotes pancreatic ductal adenocarcinoma invasion and metastasis by activating transcription of the actin-bundling protein fascin. Cancer Res 74:2455–2464. https://doi.org/10.1158/0008-5472.CAN-13-3009.
   PubMed Web of Science ®Google Scholar
• Anderson S, Poudel KR, Roh-Johnson M, Brabletz T, Yu M, Borenstein-Auerbach N, Grady WN, Bai J, Moens CB, Eisenman RN, Conacci-Sorrell M. 2016. MYC-nick promotes cell migration by inducing fascin expression and Cdc42 activation. Proc Natl Acad Sci USA 113:E5481–E5490. https://doi.org/10.1073/pnas.1610994113.
   PubMed Web of Science ®Google Scholar
• Xue M, Pang H, Li X, Li H, Pan J, Chen W. 2016. Long non-coding RNA urothelial cancer-associated 1 promotes bladder cancer cell migration and invasion by way of the hsa-miR-145-ZEB1/2-FSCN1 pathway. Cancer Sci 107:18–27. https://doi.org/10.1111/cas.12844.
   PubMed Web of Science ®Google Scholar
• Li A, Morton JP, Ma Y, Karim SA, Zhou Y, Faller WJ, Woodham EF, Morris HT, Stevenson RP, Juin A, Jamieson NB, MacKay CJ, Carter CR, Leung HY, Yamashiro S, Blyth K, Sansom OJ, Machesky LM. 2014. Fascin is regulated by slug, promotes progression of pancreatic cancer in mice, and is associated with patient outcomes. Gastroenterology 146:1386–1396.E17. https://doi.org/10.1053/j.gastro.2014.01.046.
   PubMed Web of Science ®Google Scholar
• Hashimoto Y, Loftis DW, Adams JC. 2009. Fascin-1 promoter activity is regulated by CREB and the aryl hydrocarbon receptor in human carcinoma cells. PLoS One 4:e5130. https://doi.org/10.1371/journal.pone.0005130.
   Web of Science ®Google Scholar
• Vignjevic D, Schoumacher M, Gavert N, Janssen KP, Jih G, Lae M, Louvard D, Ben-Ze’ev A, Robine S. 2007. Fascin, a novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancer. Cancer Res 67:6844–6853. https://doi.org/10.1158/0008-5472.CAN-07-0929.
   PubMed Web of Science ®Google Scholar
• Grothey A, Hashizume R, Ji H, Tubb BE, Patrick CW, Jr, Yu D, Mooney EE, McCrea PD. 2000. C-erbB-2/HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. Oncogene 19:4864–4875. https://doi.org/10.1038/sj.onc.1203838.
   PubMed Web of Science ®Google Scholar
• Feng Y, Zhu J, Ou C, Deng Z, Chen M, Huang W, Li L. 2014. MicroRNA-145 inhibits tumour growth and metastasis in colorectal cancer by targeting fascin-1. Br J Cancer 110:2300–2309. https://doi.org/10.1038/bjc.2014.122.
   PubMed Web of Science ®Google Scholar
• Liu R, Liao J, Yang M, Sheng J, Yang H, Wang Y, Pan E, Guo W, Pu Y, Kim SJ, Yin L. 2012. The cluster of miR-143 and miR-145 affects the risk for esophageal squamous cell carcinoma through co-regulating fascin homolog 1. PLoS One 7:e33987. https://doi.org/10.1371/journal.pone.0033987.
   PubMedGoogle Scholar
• Gotte M, Mohr C, Koo CY, Stock C, Vaske AK, Viola M, Ibrahim SA, Peddibhotla S, Teng YH, Low JY, Ebnet K, Kiesel L, Yip GW. 2010. miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. Oncogene 29:6569–6580. https://doi.org/10.1038/onc.2010.386.
   PubMed Web of Science ®Google Scholar
• Bae SH, Sung SH, Lee HE, Kang HT, Lee SK, Oh SY, Woo HA, Kil IS, Rhee SG. 2012. Peroxiredoxin III and sulfiredoxin together protect mice from pyrazole-induced oxidative liver injury. Antioxid Redox Signal 17:1351–1361. https://doi.org/10.1089/ars.2011.4334.
   PubMed Web of Science ®Google Scholar
• Kim H, Lee GR, Kim J, Baek JY, Jo YJ, Hong SE, Kim SH, Lee J, Lee HI, Park SK, Kim HM, Lee HJ, Chang TS, Rhee SG, Lee JS, Jeong W. 2016. Sulfiredoxin inhibitor induces preferential death of cancer cells through reactive oxygen species-mediated mitochondrial damage. Free Radic Biol Med 91:264–274. https://doi.org/10.1016/j.freeradbiomed.2015.12.023.
   PubMed Web of Science ®Google Scholar
• Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. 2004. Rational siRNA design for RNA interference. Nat Biotechnol 22:326–330. https://doi.org/10.1038/nbt936.
   PubMed Web of Science ®Google Scholar